Side effects of sedating antihistamines
Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Management of pruritus: Oral: 25 mg 3-4 times/day Intravenous, intra-arterial, and subcutaneous administration are Adult (usual) Allergy: 25 mg orally at bedtime or 12.5 mg orally before meals and at bedtime. Please review the latest applicable package insert for additional information and possible updates.
Diphenhydramine hydrochloride is widely distributed throughout the body, including the CNS. Allergy: 25 mg IV or IM, may repeat within 2 hrs if needed. A local search option of this data can be found here. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE.
[see Warnings and Precautions (5.5)] Adults and Adolescents 12 years of age and older: 7.5 m L to 20 m L (6 to 16 mg) every 12 hours Children 2 to 11 years of age (approximately 0.2 to 0.4 mg/kg/day): 2 to 3 years: 3.75 m L to 5 m L (3 to 4 mg) every 12 hours 4 to 5 years: 3.75 m L to 10 m L (3 to 8 mg) every 12 hours 6 to 11 years: 7.5 m L to 15 m L (6 to 12 mg) every 12 hours HOW SUPPLIED: Extended-release oral suspension containing 4 mg carbinoxamine maleate per 5 m L Adult (usual): 4 mg po every 4 to 6 hrs; maximum dose: 24 mg/day.
Sustained-release: 8 or 12 mg po every 8 to 12 hours. Supplied: Extended Release Cap: 6 mg, 8 mg, 12 mg Liquid/syrup: 2 mg/5 ml Tablet: 2 mg, 4 mg.
Claritin-D 24 hour (10mg loratadine 240mg psuedophedrine) Dosing (Adult): one tablet po qd. Approval: 2013 Mechanism of Action: Carbinoxamine is an H1 receptor antagonist (antihistamine) that exhibits anticholinergic (drying) and sedative properties.
Antihistamines appear to compete with histamine for cell receptor sites on effector cells. Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA).
Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. Dosing: Oral: Children: 6-11 months: 1 mg once daily 12 months to 5 years: 1.25 mg once daily 6-11 years: 2.5 mg once daily Children /= 12 years and Adults: 5 mg once daily Supplied Syrup (Clarinex®): 0.5 mg/m L (480 m L) [bubble gum flavor] Tablet (Clarinex®): 5 mg Tablet, orally-disintegrating (Clarinex® Redi Tabs®): 5 mg [contains phenylalanine 1.75 mg/tablet] Adult (usual) Chronic idiopathic urticaria: 60 mg orally twice daily.
Seasonal allergic rhinitis: 60 mg orally twice daily or 180 mg once daily.
Receptor binding data indicate that at a concentration of 2–3 ng/m L (7 nanomolar), desloratadine shows significant interaction with the human histamine H1-receptor.
Desloratadine inhibited histamine release from human mast cells in vitro.
Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.